Treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy at first relapse in patients with B-cell non-Hodgkin’s lymphoma is associated with higher response rates and longer durations of response than as a more delayed treatment option: Results from a retrospective analysis